Clinical features of talaromycosis in people living with HIV/AIDS (PWHA) and patients with anti-interferon-γ autoantibodies
PLOS Neglected Tropical Diseases · 2025
DOI: 10.1371/journal.pntd.0012992 ↗Kurz gefasst
Fachartikel in der Zeitschrift PLOS Neglected Tropical Diseases, 2025. Verfasst von Kawisara Krasaewes und 6 weiteren Autor:innen. Beteiligte Einrichtung: Division of Infectious Diseases and Tropical Medicine, Department of Internal Medicine, Faculty of Medicine Chiang Mai University, Chiang Mai, Thaila…. Hauptthemen laut MEDLINE: Interferon-gamma, Autoantibodies, HIV Infections, Mycoses. Die Arbeit nennt 26 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Background
Talaromycosis is increasingly reported in HIV-uninfected, immunocompromised individuals in an endemic area. The aim of this study was to compare the characteristics and mortality associated with talaromycosis in adult immunocompromised individuals caused by the anti-interferon-gamma autoantibody (anti-IFN- γ AAb) with those of people living with HIV/AIDS (PWHA).
Methods
A retrospective cohort study was conducted at Maharaj Nakorn Chiang Mai Hospital, Thailand, in adults with confirmed HIV infection or anti-IFN- γ-AAbs diagnosed with talaromycosis.
Results
Thirty-two patients with anti-IFN- γ-AAbs and 235 PWHA were included. Patients with anti-IFN- γ-AAbs were older and more likely to have comorbidities. PWHA were more likely to have constitutional symptoms, cough, dyspnea, diarrhea, splenomegaly, umbilicated skin lesions, abnormal chest radiographs, and fungemia. Patients with anti-IFN- γ-AAbs were more likely to have skin lesions such as macule/papules/nodules, abscesses and Sweet’s syndrome, as well as bone and joint infections and higher white blood cell counts. The time from first symptom to treatment was longer in patients with anti-IFN- γ-AAbs (44.5 days vs. 30.0 days, p-value = 0.049). The 24-week mortality rate was 9.4% (3 patients) in patients with anti-IFN- γ-AAbs and 15.3% (36 patients) in PWHA (p-value = 0.372).
Conclusions
The clinical features of talaromycosis in patients with anti-IFN- γ-AAbs differed from PWHA. Clinicians in areas where talaromycosis is endemic should be aware of the different features of talaromycosis in patients with anti-IFN- γ AAbs.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Division of Infectious Diseases and Tropical Medicine, Department of Internal Medicine, Faculty of Medicine Chiang Mai University, Chiang Mai, Thailand.
- Department of Internal Medicine, Faculty of Medicine Chiang Mai University, Chiang Mai, Thailand.
- Department of Internal Medicine, University of Iowa, Iowa City, Iowa, United States of America.
- Research Institute for Health Sciences, Chiang Mai University, Chiang Mai, Thailand.
ORCID-Profile: Romanee Chaiwarith
Zitieren
APA
Krasaewes, K., Patanadamrongchai, N., Kaewpoowat, Q., Wipasa, J., Yasri, S., Wongthanee, A., & Chaiwarith, R. (2025). Clinical features of talaromycosis in people living with HIV/AIDS (PWHA) and patients with anti-interferon-γ autoantibodies. PLOS Neglected Tropical Diseases. https://doi.org/10.1371/journal.pntd.0012992
Vancouver
Krasaewes K, Patanadamrongchai N, Kaewpoowat Q, Wipasa J, Yasri S, Wongthanee A, et al. Clinical features of talaromycosis in people living with HIV/AIDS (PWHA) and patients with anti-interferon-γ autoantibodies. PLOS Neglected Tropical Diseases. 2025. doi:10.1371/journal.pntd.0012992
BibTeX
@article{Krasaewes2025,
author = {Krasaewes, Kawisara and Patanadamrongchai, Narootchai and Kaewpoowat, Quanhathai and Wipasa, Jiraprapa and Yasri, Saowaluck and Wongthanee, Antika and Chaiwarith, Romanee},
title = {Clinical features of talaromycosis in people living with HIV/AIDS (PWHA) and patients with anti-interferon-γ autoantibodies},
journal = {PLOS Neglected Tropical Diseases},
year = {2025},
doi = {10.1371/journal.pntd.0012992}
}
EUVIMED